Premenstrual syndrome (PMS) frequently occurs in women of childbearing age. There are different case definitions of PMS, one proposed by the American College of Obstetricians and Gynecologists (ACOG) and another based on the Daily Record of Severity of Problems (DRSP) scores. Here we review our recent papers indicating that the discovery of biomarkers of menstrual cycle-related symptoms is strongly dependent on the case definitions used and that the gold standard methods used to asses PMS, including the ACOG case definition, induce a high degree of false-negative findings. We propose a new case definition of the menstrual cycle-associated syndrome (MCAS), which is characterized by increased DRSP scores during the menstrual cycle and additionally by an exaggerated increase in symptoms the week prior to the menses. This case definition performed well and was externally validated by diverse biomarkers including plasma levels of progesterone and estradiol, chemokines (e.g. CCL2, CCL5 and CCL11), epidermal growth factor, hydroperoxides, paraoxonase 1 activity and complement C4. In conclusion, when evaluating menstrual cycle-related symptoms and their associations with biomarkers, we propose to assess daily measurements of the DRSP and based on those scores to a) use the diagnosis of MCAS as an indicant of menstrual cycle-related symptoms; and b) examine the associations of the time series in the DRSP and its subdomains (e.g. depression, physio-somatic, anxiety) and those in biomarkers including distributed lag models.
Abstract
Premenstrual syndrome (PMS) frequently occurs in women of childbearing age. There are different case definitions of PMS, one proposed by the American College of Obstetricians and Gynecologists (ACOG) and another based on the Daily Record of Severity of Problems (DRSP) scores. Here we review our recent papers indicating that the discovery of biomarkers of menstrual cycle-related symptoms is strongly dependent on the case definitions used and that the gold standard methods used to asses PMS, including the ACOG case definition, induce a high degree of false-negative findings. We propose a new case definition of the menstrual cycle-associated syndrome (MCAS), which is characterized by increased DRSP scores during the menstrual cycle and additionally by an exaggerated increase in symptoms the week prior to the menses. This case definition performed well and was externally validated by diverse biomarkers including plasma levels of progesterone and estradiol, chemokines (e.g. CCL2, CCL5 and CCL11), epidermal growth factor, hydroperoxides, paraoxonase 1 activity and complement C4. In conclusion, when evaluating menstrual cycle-related symptoms and their associations with biomarkers, we propose to assess daily measurements of the DRSP and based on those scores to a) use the diagnosis of MCAS as an indicant of menstrual cycle-related symptoms; and b) examine the associations of the time series in the DRSP and its subdomains (e.g. depression, physio-somatic, anxiety) and those in biomarkers including distributed lag models.
Introduction
Premenstrual syndrome (PMS) and the classical diagnosis of PMS Premenstrual syndrome (PMS) is characterized by recurrent physical, emotional, and behavioral symptoms which develop during the second half (luteal phase) of the menstrual cycle and disappear within a few days after menstruation 1 . PMS occurs in 50-80% of reproductive-age women ranged from mild to severe. The symptoms of PMS comprise irritability, sadness, depression, mood swings, decreased concentration, sleep problems, fatigue, bloating, and breast discomfort, which all together may disturb abilities of these women to function normally 2 .
Different case definitions are used to make the diagnosis of PMS. A first is based on assessments of the Daily Record of Severity of Problems (DRSP) 3 , which was developed as a tool to screen for DSM-IV criteria for Premenstrual Dysphoric Disorder (PMDD) 3 . The DRSP is useful in women who are suspected to have PMS to self-rate the severity of symptoms associated with PMS 3 and to confirm the appearance of symptoms during the luteal phase and the normalization of those symptoms within a few days after menses and the follicular phase.
Many studies have applied the DRSP to make the diagnosis of PMS for example by using a) a cutoff value of 50 on the first day of menses to screen for premenstrual disorders [3] [4] [5] , and b) a DRSP score of at least 70 on day -5 to -1 of the cycle coupled with a difference of at least 30% between the premenstrual (day -5 to -1) and postmenstrual (day 6-10) DRSP score to diagnose PMS 6 .
Another case definition of PMS, which is widely used in clinical settings, is that proposed by the American College of Obstetricians and Gynecologists (ACOG) 7 . ACOG criteria consider PMS when one or more affective and physical symptoms are present 5 days prior to the menses and when symptomatic remission occurs within 4 days after the onset of menses without symptom recurrence until at least day 13 of the next cycle. This pattern should occur for at least 3 consecutive menstrual cycles with significant dysfunctions in social, academic, or work performance during the symptomatic phase 7 .
New case definitions
Recently, we investigated the alterations in the DRSP scores, which were assessed on a daily basis, in 41 women namely 21 with and 20 without increased PMS symptoms as assessed using a DRSP score of 50 on the first day of the menses [3] [4] [5] . We In our studies 11 , we also examined the factor structure of the DRPS items in order to detect meaningful latent constructs that could be used as severity indices of relevant symptom domains. We detected 4 interpretable factors with eigenvalues > 1 and explaining 73.11% of the variance, with the first rotated principal factor (PC) explaining 20.14% of the variance and loading highly on depression, mood swings, sensitive to rejection, angry-irritable, more conflicts, less interest, out of control, and interference with hobbies and relationships, consequently named the "depressive dimension". The second rotated PC explained 18.02% of the variance and loaded highly on concentration disturbances, lethargy, sleepiness, headache, muscle/joint pain and lowered productivity, named as the "physio-somatic dimension". The third rotated PC explained 17.83% of the variance and loaded highly on appetite and craving and breast tenderness and swelling, named the "eating & breast PC". The fourth rotated PC explained 17.11% of the variance and scored highly on hopelessness, anxious, lethargy, insomnia, being overwhelmed, and muscle-joint pain and was therefore named as "anxiety PC".
Clinical validation of the old and newly proposed PMS case definitions
In order to externally validate the different case definitions (i.e., PMS, ACOG, PeriMS, and MCAS) we examined the effects of diagnosis (differences in the DRSP score between women with and without the case definition) and time (4 time points) x diagnosis. The best case definition to capture increased severity of premenstrual symptoms was defined as the one that detects the strongest increase in the DRSP scores in the premenstrual period as indicated by the highest impact of the time x diagnosis interaction. The best case definition reflecting increased DRSP values all over the menstrual cycle is the one that showed the greatest differences in the sum of the 28 daily DRSP measurements between the 4 case definitions. Interestingly, we found that the PeriPMS and MCAS case definitions showed the most significant interaction patterns as well as the highest intergroup differences, while both the ACOG and PMS case definitions showed nearly no group differences and less significant interaction patterns. Thus, in women with the PeriMS and MCAS case definitions, higher DRSP values at all time points were found as compared to women without those case definitions while those differences were significantly pronounced in the week prior to the menses. As such, both the MCAS and PeriMS case definitions reflect increases in DRSP the week before the menses as well as higher DRSP levels during the whole menstrual cycle.
Phrased differently, increased DRSP levels all over the cycle appear to be associated with highly significant increases in the DRSP score the week prior to the menses and a lowering of the scores the weeks after the menses.
In contrast, applying the ACOG diagnostic criteria showed that the DRSP score at T1, T2 and T3 were not significantly different between women with and without that case definition while the differences at T4 were only marginally different. As such, the diagnosis of 
Biomarkers validation of the PMS case definitions
We also examined the external validation of the four different case definitions using biomarkers of the menstrual cycle. Firstly, we examined whether sex hormones could be used to externally validate one or more of the case definitions. Therefore, we examined T1, T2, T3
and T4 estradiol and progesterone levels and found that the plasma steady-state levels of estradiol and progesterone were significantly lowered in subjects with PMS, PeriMS and MCAS, but not ACOG, as compared with women without that case definition 11 . Moreover, the diagnosis of PMS was only predicted by steady state levels of progesterone, while the PeriMS and MCAS diagnoses were significantly related to both estradiol and progesterone 11 .
As such, the case definitions of PeriMS and MCAS, but not ACOG or PMS, were externally validated by lower levels of both sex hormones.
Secondly, we also examined changes in plasma levels of chemokines, namely CCL2
(C-C motif ligand 2), CCL5 (C-C motif ligand 5 or RANTES) and CCL11 (C-C motif ligand 11 or eotaxin), and EGF (epidermal growth factor) throughout the menstrual cycle in relation to the 4 case definitions 12 . This research revealed that CCL2, CCL5, CCL11 and EGF are significantly higher in women with MCAS than in women without MCAS, whereas there were no differences in those biomarkers between women with and without ACOG, PMS, and
PeriMS. As such, the case definition MCAS was externally validated by increased plasma levels of chemokines and EGF, whereas PeriMS, PMS and ACOG could not be validated.
Thirdly, we also measured immune (e.g. complement C4) and oxidative stress (e.g. dimensions. Moreover, we also examined distributed lag models whereby current as well as lagged (1 week) values of sex hormones predicted the changes in DRSP scores. Doing so, we observed that the "depressive" and "physio-somatic" symptom domain scores were significantly predicted by the lagged progesterone values, whilst the repeated measurements of the "anxiety PC" and the "eating-breast PC" were best predicted by steady state levels of progesterone and its lagged values 11 .
Moreover, the DRSP and subdomain scores all over the menstrual cycle were significantly associated with steady-state levels of CCL2 and CCL5 (Roomruangwong et al., submitted) while a newly composed index reflecting the effects of the neurotoxic chemokines CCL2, CCL5 and CCL11 was significantly associated not only with the DRSP total score, but also with the "depressive", "physio-somatic", "breast-craving" and "anxiety" subdomain scores.
We also observed significant changes in the IgA levels directed to LPS of various gut commensal Gram-negative bacteria across the menstrual cycle with peak changes at T4 (day 28), but lows at T1 (day 7) and T2 (day 14). Additionally, changes in Hafnia alvei, Morganella.
morganii and Pseudomonas putida were significantly associated with changes in the total DRSP scores and 2 subdomains namely "physio-somatic" and "breast-craving". H. alvei was also detected to be associated with "anxiety" subdomain 13 . Lastly, we also found that changes in the DRSP score were significantly associated with changes in PON1 activity, MDA and C4
(lagged values) and that the severity of the subdomain scores was associated with those biomarkers or with LOOH levels (Roomruangwong et al., submitted).
Conclusions
Our results show that the discovery of new biomarkers of menstrual cycle-related symptoms is strongly dependent on the case definition used to assess those symptoms. The classical methods used to asses PMS including the ACOG case definition induce a high degree of type 2 errors or false-negative findings, while these methods do not allow to capture all aspects of the clinical picture including the continuous increase in DRSP scores and its subdomains during the menstrual cycle. Therefore, menstrual cycle-related symptoms cannot be adequately assessed using case definitions that are based on the severity of premenstrual symptoms coupled with a (partial) remission after the menses. In this paper we propose a new case definition of MCAS, which performed well and could be clinically and biologically validated. By inference, the best method to evaluate menstrual cycle-related symptoms and their associations with biomarkers is to assess daily measurements of those symptoms using the DRSP and based on those scores to a) make the diagnosis of MCAS, which reflects increased severity (overall and subdomains) during the menstrual cycle coupled with an incremental increase in the premenstrual period; b) examine the total DRSP score as well as its four subdomains; c) examine the associations of the time series in the DRSP score and those in biomarkers including using distributed lag models, which allow to predict the clinical scores by biomarkers measured some days earlier.
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